Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3326101 | 1.00 | MEN1 (0.48) | MEN1KMT2ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL3324520 | 0.89 | HRH3 (0.56) | HRH3 | |
| SCHEMBL3325886 | 0.89 | HRH3 (0.56) | HRH3 | |
| SCHEMBL3324522 | 0.89 | HRH3 (0.56) | HRH3 | |
| SCHEMBL3327455 | 0.89 | HRH3 (0.53) | HRH3 | |
| SCHEMBL3324027 | 0.88 | HRH3 (0.52) | MEN1KMT2AALDH1A1KDM4EHRH3 | |
| SCHEMBL3330185 | 0.88 | HRH3 (0.52) | MEN1KMT2AALDH1A1KDM4EHRH3 | |
| SCHEMBL3324024 | 0.88 | HRH3 (0.52) | MEN1KMT2AALDH1A1KDM4EHRH3 | |
| SCHEMBL3330189 | 0.88 | HRH3 (0.52) | MEN1KMT2AALDH1A1KDM4EHRH3 | |
| SCHEMBL3323116 | 0.79 | CHRNB2 (0.55) | KMT2AMAPTEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120769-A1 | CYCLOHEXYL PIPERAZINYL METHANONE DERIVATIVES | NETTEKOVEN MATTHIAS | 2010-05-13 | — | — | US | disclosed |
| US-20070167436-A1 | Cyclohexyl piperazinyl methanone derivatives | HOFFMANN-LA ROCHE INC. | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120769-A1 | CYCLOHEXYL PIPERAZINYL METHANONE DERIVATIVES | HRH3, HRH4, HRH1 | MEN1 1237/4885KMT2A 291/4885SMN1; SMN2 2460/4885 |
| US-20070167436-A1 | Cyclohexyl piperazinyl methanone derivatives | HRH3, HRH4, HRH1 | MEN1 1237/4885KMT2A 291/4885SMN1; SMN2 2460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.